SYRE Q1 2024 Earnings — Spyre Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SYRESpyre Therapeutics, Inc.

$3B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$48M

Net Income

-$44M

EPS (Diluted)

$-1.20

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$29M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$488M

Total Liabilities

$335M

Stockholders' Equity

$152M

Cash & Equivalents

$228M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$198,000	-100.0%
Gross Profit	$0	-$350,000	+100.0%
Operating Income	-$48M	-$19M	-154.0%
Net Income	-$44M	-$18M	-138.1%